|
Post by actcfan on May 11, 2017 16:02:57 GMT
Some info in this report worth a read. Below info related to Keytruda costs which would be about $70k for 24 works (the primary endpoint): Considering the price of Keytruda is approximately $12,500 per month, this drug supply agreement represents substantial cost savings for OncoSec.
Dosing of the agents will be similar to the ongoing Phase II combination trial, which includes ImmunoPulse IL-12 on days 1, 5, and 8 every 6 weeks and Keytruda dosed at its normal interval. 48 patients in total are estimated to enroll in this study. The primary endpoint to support a potential accelerated approval will be ORR at 24 weeks as measured by RECIST 1.1 criteria. lifesci.bluematrix.com/sellside/EmailDocViewer?encrypt=26053911-879d-4272-86d8-d98f925c0f8e&mime=pdf&co=Lifesci
|
|
|
Post by jckrdu on May 11, 2017 21:59:16 GMT
Another article with a mention of ONCS. Shareprice is in the toilet, but at least some folks are taking notice. 247wallst.com/healthcare-business/2017/05/11/why-big-pharma-is-not-at-fault-for-record-drug-spending/On the very same day Merck announced a collaboration with OncoSec Medical Inc. (NASDAQ: ONCS) on combining Keytruda with OncoSec’s ImmunoPulse IL-12 electroporation melanoma therapy in a registrational Phase 2 trial. The goal is to expand Keytruda’s market dramatically to previous nonresponders, which make up 60% to 80% of the melanoma population.
|
|
|
Post by selluwud on Oct 11, 2017 22:29:24 GMT
Another article with a mention of ONCS. Shareprice is in the toilet, but at least some folks are taking notice. 247wallst.com/healthcare-business/2017/05/11/why-big-pharma-is-not-at-fault-for-record-drug-spending/On the very same day Merck announced a collaboration with OncoSec Medical Inc. (NASDAQ: ONCS) on combining Keytruda with OncoSec’s ImmunoPulse IL-12 electroporation melanoma therapy in a registrational Phase 2 trial. The goal is to expand Keytruda’s market dramatically to previous nonresponders, which make up 60% to 80% of the melanoma population. I was able to sell some at 1.34 , hoping to buy back in when possible
|
|